Peptide LibraryPemvidutide dosage in published studies and labels
These are the doses used for Pemvidutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Pemvidutide has no approved dosage. Human dosing comes from Altimmune's trials of once-weekly injections under the skin of 1.2, 1.8 or 2.4 mg: in the IMPACT phase 2b trial in MASH with fibrosis, 1.2 mg and 1.8 mg without titration met the goal of MASH resolution at 24 weeks but not the fibrosis goal. A phase 3 MASH trial of 1.8 mg and 2.4 mg is recruiting.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.2–2.4 mg once weekly in trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 12–48 weeks in the reported trials |
| Titration | IMPACT gave its doses without titration. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| IMPACT — phase 2b, MASH with fibrosis (NCT05989711)Clinical trial · Randomized, double-blind, placebo-controlled phase 2b trial | Adults with biopsy-confirmed MASH and fibrosis stage F2–F3 (n=212) | 1.2 mg or 1.8 mg, without dose titration | Subcutaneous | Once weekly | 24-week results of a 48-week trial | MASH resolution without worse fibrosis in 58% (1.2 mg) and 52% (1.8 mg) against 20% with placebo; the fibrosis-improvement endpoint was not met | Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. |
| Phase 1b, MASLD (NCT05006885)Clinical trial · Randomized, double-blind, placebo-controlled trial | Adults with BMI ≥28 and liver fat ≥10% (n=94) | 1.2, 1.8 or 2.4 mg | Subcutaneous | Once weekly | 12 weeks | Relative liver-fat reduction of 46.6%, 68.5% and 57.1% against 4.4% with placebo; weight change up to -4.3% at 1.8 mg | Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. |
| MOMENTUM — phase 2, obesity (NCT05295875)Clinical trial · Phase 2 randomized, placebo-controlled trial | Adults with obesity (n=391) | Three dose levels; amounts not given in the registry | Subcutaneous | Per trial protocol | 48 weeks (primary endpoint) | Completed; no results posted on ClinicalTrials.gov | NCT05295875 — Efficacy and Safety of ALT-801 in the Treatment of Obesity |
| Phase 3, MASH outcomes (NCT07795164)Clinical trial · Phase 3 randomized, placebo-controlled trial | Adults with MASH (n=1,800 planned) | 1.8 mg or 2.4 mg | Subcutaneous | Per trial protocol | About 60 months for clinical outcomes; histology at week 52 | Recruiting; no results | NCT07795164 — Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH |
Where sources disagree
- IMPACT met one of its two primary endpoints (MASH resolution) but not the other (fibrosis improvement) at 24 weeks.
- The code ALT-801 was also used for an unrelated interleukin-2 fusion protein studied in cancer. Papers and registry entries about that ALT-801 are not evidence about pemvidutide.
- Pemvidutide is not FDA-approved.